Möchten Sie immer auf dem neuesten Stand bleiben?

New York, USA, April 01, 2026 (GLOBE NEWSWIRE) -- Systemic Lupus Erythematosus Clinical Trial Pipeline Accelerates as 120+ Pharma Companies Rigorously Developing Drugs for Market Entry |...

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.  The proposed transactions may contain terms that could limit superior competing offers. ...

Acquisition will bring two differentiated commercialized immunology medicines to Biogen with EMPAVELI® FDA-approved in three indications, including two rare kidney diseases, and SYFOVRE® FDA-approved...

Acquisition will bring two differentiated commercialized immunology medicines to Biogen with EMPAVELI® FDA-approved in three indications, including two rare kidney diseases, and SYFOVRE® FDA-approved...

The approval was anchored on data from the pivotal DEVOTE study that investigated the efficacy and safety of the High Dose Regimen of SPINRAZA in treatment-naïve and previously treated SPINRAZA...

In the Phase 2 part of the AMETHYST study, litifilimab met the primary endpoint of reduction of disease activity in people living with CLE at Week 16, with more litifilimab participants achieving...

CAMBRIDGE, Mass., March 24, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of...

TOKYO and CAMBRIDGE, Mass., March 20, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge,...

BOSTON, March 19, 2026 (GLOBE NEWSWIRE) -- Block & Leviton LLP announces that the United States District Court for the District of Massachusetts has approved the following announcement of the...

Late-breaking AMETHYST Part A study results to be presented, showing safety and efficacy of litifilimab in cutaneous lupus erythematosus (CLE)Litifilimab was recently granted Breakthrough Therapy...